Carbamazepine

卡马西平

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameCarbamazepine
Drug Alias Name酰胺咪嗪carbamazepinacarbamazepinum氨甲酰氮卓卡巴西平 +[27] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsBipolar DisorderCocaine-Related DisordersSubstance-Related Disorders +[13] 
Global Approved IndicationsBipolar DisorderSeizuresPsychomotor Agitation +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved DateN/A
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesYuyu PharmaValidus Pharmaceuticals LlcNovartis Pharma Ag +[4] 
Inactive CompaniesValidus PharmaceuticalsWashington University School Of MedicineLundbeck Llc +[5] 
Active IndicationsBipolar DisorderDiabetes InsipidusSeizures +[9] 
Inactive IndicationsCocaine-Related DisordersSubstance-Related DisordersLiver Cirrhosis +[4] 

Other Information

ATC CodeN03AF01
Related LinksWikipediaDrugBankKEGG